Ethanol potentiates tumor necrosis factor-alpha cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition.
In the present study, tumor necrosis factor-alpha (TNF-alpha) cytotoxicity is shown to be potentiated by ethanol exposure in vitro in the human hepatoma cell line, HepG2, and in rat primary hepatocytes. Exposure of HepG2 cells and primary hepatocytes for 48 hours to concentrations of ethanol ranging between 50 and 100 mmol/L significantly increased TNF-alpha cytotoxicity compared with cells treated with TNF-alpha alone. The cell killing was associated with, and dependent on, the development of the mitochondrial permeability transition (MPT). Two inhibitors of MPT pore opening, cyclosporin A and bongkrekic acid, prevented TNF-alpha cytotoxicity in the presence of ethanol. In addition to inhibiting cell death caused by TNF-alpha, blockade of MPT pore opening prevented mitochondrial depolarization, cytochrome c redistribution from the mitochondria to the cytosol, caspase 3 activation, and oligonucleosomal DNA fragmentation. Unlike the potentiation of TNF-alpha cytotoxicity by the translational inhibitor cycloheximide, ethanol promoted TNF-alpha-induced cell killing by a mechanism that was independent of caspase-8 activity. HepG2 cells overexpressing cytochrome-P4502E1 were even more sensitized by ethanol to induction of the MPT by TNF-alpha and the resultant cytotoxicity than wild-type HepG2 cells. In addition, primary hepatocytes isolated from chronically ethanol-fed rats showed enhanced susceptibility to TNF-alpha cytotoxicity compared with their isocalorically matched controls. Again as with the HepG2 cells, inhibiting MPT pore opening prevented the cytotoxicity of TNF-alpha in the primary hepatocytes isolated from ethanol-fed animals.
Pastorino
J G
JG
Thomas Jefferson University, Department of Pathology, Anatomy, and Cell Biology, Philadelphia, PA 19107, USA. John.Pastorino@mail.tju.edu
Hoek
J B
JB
D000818:Animals; D053148:Caspase 3; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases / Q000378:metabolism / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects; D016572:Cyclosporine / Q000494:pharmacology; D019392:Cytochrome P-450 CYP2E1 / Q000502:physiology; D003574:Cytochrome c Group / Q000378:metabolism; D004357:Drug Synergism; D000431:Ethanol / Q000633:toxicity*; D006801:Humans; D008099:Liver / Q000166:cytology; D008113:Liver Neoplasms / Q000378:metabolism; D008297:Male; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000378:metabolism; D010539:Permeability; D051381:Rats; D017207:Rats, Sprague-Dawley; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000633:toxicity*
D003574:Cytochrome c Group; D014409:Tumor Necrosis Factor-alpha; D000431:Ethanol; D016572:Cyclosporine; D019392:Cytochrome P-450 CYP2E1; C505407:CASP3 protein, human; C505530:CASP8 protein, human; C506433:CASP9 protein, human; C505410:Casp3 protein, rat; C505528:Casp8 protein, rat; C506435:Casp9 protein, rat; D053148:Caspase 3; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases